https://www.dsru.org/abstract/abstract-1823-sources-of-evidence-supporting-post-marketing-pharmacovigilance-regulatory-actions-since-2012/ 2025-08-12T10:24:02+00:00 https://www.dsru.org/abstract/abstract-2085-passive-enhanced-safety-surveillance-in-children-receiving-fluenz-tetra-vaccination-in-england-during-the-early-2017-influenza-season/ 2025-08-12T10:24:03+00:00 https://www.dsru.org/abstract/abstract-2051-incidence-of-major-and-clinically-relevant-non-major-crnm-bleeding-in-patients-prescribed-rivaroxaban-in-secondary-care-results-from-the-rivaroxaban-observational-safety-evaluation/ 2025-08-12T10:24:04+00:00 https://www.dsru.org/abstract/abstract-2521-assessment-of-initiation-dose-in-patients-prescribed-rivaroxaban-for-stroke-prevention-in-non-valvular-af-spaf-and-chronic-kidney-disease-results-from-the-rose-rivaroxaban/ 2025-08-12T10:24:05+00:00 https://www.dsru.org/abstract/abstract-2516-characteristics-of-patients-initiated-on-a-reduced-dose-of-rivaroxaban-for-atrial-fibrillation-af-results-from-the-rose-rivaroxaban-observational-safety-evaluation-study/ 2025-08-12T10:24:06+00:00 https://www.dsru.org/abstract/abstract-2082-distribution-of-cha2ds2-vasc-scores-in-patients-with-atrial-fibrillation-treated-with-rivaroxaban-in-primary-vs-secondary-care-settings/ 2025-08-12T10:24:07+00:00 https://www.dsru.org/abstract/abstract-274-risk-factors-of-major-bleeding-in-patients-prescribed-rivaroxaban-in-primary-care-in-england-based-on-a-modified-prescription-event-monitoring-study/ 2025-08-12T10:24:32+00:00 https://www.dsru.org/abstract/abstract-273-a-cross-sectional-study-of-product-and-batch-traceability-for-biologics-in-clinical-practice-and-adverse-drug-reaction-reporting-in-the-united-kingdom/ 2025-08-12T10:24:34+00:00 https://www.dsru.org/abstract/abstract-272-changes-in-evidence-supporting-post-marketing-withdrawal-of-marketing-authorisation-in-the-eu/ 2025-08-12T10:24:35+00:00 https://www.dsru.org/abstract/abstract-270-distribution-of-cha2ds2-vasc-scores-in-patients-with-atrial-fibrillation-treated-with-rivaroxaban-in-primary-vs-secondary-care-settings/ 2026-07-23T14:45:17+00:00 https://www.dsru.org/abstract/abstract-269-assessment-of-start-dose-in-patients-prescribed-rivaroxaban-for-atrial-fibrillation-with-chronic-kidney-disease-results-from-the-rose-study/ 2026-07-23T15:05:53+00:00 https://www.dsru.org/abstract/abstract-268-characteristics-of-patients-started-on-a-reduced-dose-of-rivaroxaban-for-atrial-fibrillation-results-from-the-rose-study/ 2026-07-23T15:14:56+00:00 https://www.dsru.org/abstract/abstract-267-incidence-of-major-and-clinically-relevant-non-major-bleeding-in-patients-prescribed-rivaroxaban-results-from-the-rose-study/ 2026-07-23T15:30:36+00:00 https://www.dsru.org/abstract/abstract-266-multi-level-modelling-to-investigate-factors-impacting-prescribing-variability/ 2026-07-23T15:36:05+00:00 https://www.dsru.org/abstract/abstract-265-risk-of-major-and-clinically-relevant-non-major-crnm-bleeding-in-patients-prescribed-rivaroxaban-in-primary-care-in-england/ 2026-07-23T15:43:06+00:00 https://www.dsru.org/abstract/abstract-262-passive-enhanced-safety-surveillance-in-children-receiving-fluenz-tetra-vaccination-in-england-during-the-early-2017-2018-influenza-season/ 2026-07-23T15:50:12+00:00 https://www.dsru.org/abstract/abstract-264-utilisation-and-safety-of-asenapine-in-secondary-care-in-the-uk-results-from-the-observational-safety-evaluation-of-asenapine-observa-study/ 2026-07-23T15:54:43+00:00 https://www.dsru.org/abstract/abstract-263-utilisation-and-safety-of-asenapine-in-primary-care-in-england-results-from-a-pass/ 2026-07-23T16:04:16+00:00 https://www.dsru.org/abstract/abstract-271-impact-analyses-of-eu-pharmacovigilance-interventions-on-public-health-burden/ 2026-07-23T16:08:22+00:00 https://www.dsru.org/abstract/risk-factors-of-major-bleeding-in-patients-prescribed-rivaroxaban-in-primary-care-in-england/ 2026-07-24T12:37:25+00:00 https://www.dsru.org/abstract/the-association-between-direct-oral-anticoagulants-and-gynaecological-bleeding-in-women-v-standard-therapy-a-systematic-review/ 2026-07-24T12:45:44+00:00 https://www.dsru.org/abstract/utilisation-of-dulaglutide-in-primary-care-in-england-interim-results-from-a-post-authorisation-safety-study/ 2026-07-24T12:51:28+00:00 https://www.dsru.org/abstract/utilisation-of-exenatide-once-weekly-bydureon-in-primary-care-in-england-results-from-a-pass/ 2026-07-24T12:53:59+00:00 https://www.dsru.org/abstract/monitoring-the-safety-of-exenatide-once-weekly-bydureon-in-primary-care-in-england-results-from-a-pass/ 2026-07-24T12:58:43+00:00 https://www.dsru.org/abstract/impact-analyses-of-european-pharmacovigilance-interventions-on-public-health-burden/ 2026-07-24T13:05:02+00:00 https://www.dsru.org/abstract/publication-379/ 2026-07-24T13:08:24+00:00 https://www.dsru.org/abstract/risk-of-major-and-clinically-relevant-non-major-crnm-bleeding-in-patients-prescribed-rivaroxaban-for-stroke-prevention-in-non-valvular-af-spaf-and-the-prevention-and-or-treatment-of-deep-vein-thro/ 2026-07-24T13:42:30+00:00 https://www.dsru.org/abstract/multi-level-modelling-to-investigate-factors-impacting-prescribing-variability/ 2026-07-24T13:45:05+00:00 https://www.dsru.org/abstract/abstract-2500-utilisation-and-safety-of-asenapine-in-primary-care-in-england-results-from-a-pass/ 2026-07-24T13:48:32+00:00 https://www.dsru.org/abstract/abstract-2508-utilisation-and-safety-of-asenapine-in-secondary-care-in-the-uk-results-from-the-observational-safety-evaluation-of-asenapine-observa-study/ 2026-07-24T13:53:49+00:00